Impact of Gut Microbiota and SCFAs in the Pathogenesis of PCOS and the Effect of Metformin Therapy
International Journal of Molecular Sciences · 02.10.2024 · 25 (19) · 10636
DOI: 10.3390/ijms251910636 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 02.10.2024. Verfasst von Evgenii Kukaev und 8 weiteren Autor:innen. Beteiligte Einrichtung: V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Healthcare of Russian Federation, 117997 Mosco…. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Metformin, Fatty Acids, Volatile, Gastrointestinal Microbiome. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
Polycystic ovary syndrome (PCOS) is a complex disorder that impacts both the endocrine and metabolic systems, often resulting in infertility, obesity, insulin resistance, and cardiovascular complications. The aim of this study is to investigate the role of intestinal flora and its metabolites, particularly short-chain fatty acids (SCFAs), in the development of PCOS, and to assess the effects of metformin therapy on these components. SCFA levels in fecal and blood samples from women with PCOS (n=69) and healthy controls (n=18) were analyzed using Gas Chromatography–Mass Spectrometry (GC/MS) for precise measurement. Fecal microbiota were quantitatively detected by real-time polymerase chain reaction (PCR). To assess the efficacy of six months of metformin treatment, changes in the microbiota and SCFAs in the PCOS group (n=69) were also evaluated. The results revealed that women with PCOS exhibited a significant reduction in beneficial bacteria (namely, the C. leptum group and Prevotella spp.) alongside a notable overgrowth of opportunistic microorganisms (C. perfringens, C. difficile, Staphylococcus spp., and Streptococcus spp.). An overproduction of acetic acid (AA, FC=0.47, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Healthcare of Russian Federation, 117997 Moscow, Russia.
- V.L. Talrose Institute for Energy Problems of Chemical Physics, N.N. Semenov Federal Research Center of Chemical Physics, Russian Academy of Sciences, 119334 Moscow, Russia.
- Lebedev Physical Institute, 119991 Moscow, Russia.
- Moscow Center for Advanced Studies, 123592 Moscow, Russia.
- Laboratory of Translational Medicine, Siberian State Medical University, 634050 Tomsk, Russia.
ORCID-Profile: Evgenii Kukaev, Ekaterina Kirillova, Alisa Tokareva, Elena Rimskaya, Natalia Starodubtseva, Galina Chernukha, Tatiana Priputnevich, Vladimir Frankevich, Gennady Sukhikh
Förderung
- Russian Science Foundation
Zitieren
APA
Kukaev, E., Kirillova, E., Tokareva, A., Rimskaya, E., Starodubtseva, N., Chernukha, G., Priputnevich, T., Frankevich, V., & Sukhikh, G. (2024). Impact of Gut Microbiota and SCFAs in the Pathogenesis of PCOS and the Effect of Metformin Therapy. International Journal of Molecular Sciences, 25(19), 10636. https://doi.org/10.3390/ijms251910636
Vancouver
Kukaev E, Kirillova E, Tokareva A, Rimskaya E, Starodubtseva N, Chernukha G, et al. Impact of Gut Microbiota and SCFAs in the Pathogenesis of PCOS and the Effect of Metformin Therapy. International Journal of Molecular Sciences. 2024;25(19):10636. doi:10.3390/ijms251910636
BibTeX
@article{Kukaev2024,
author = {Kukaev, Evgenii and Kirillova, Ekaterina and Tokareva, Alisa and Rimskaya, Elena and Starodubtseva, Natalia and Chernukha, Galina and Priputnevich, Tatiana and Frankevich, Vladimir and Sukhikh, Gennady},
title = {Impact of Gut Microbiota and SCFAs in the Pathogenesis of PCOS and the Effect of Metformin Therapy},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {19},
pages = {10636},
doi = {10.3390/ijms251910636}
}
EUVIMED